1078 Section 3: Anti-tumor pharmacology Doi: 10.1038/aps.2017.66 Wen-na SHI1, Shu-xiang CUI2, Zhi-yu SONG1, Shu-qing WANG1, Shi-yue SUN1, Xin-feng S3.1 YU1, Yu-hang ZHANG1, Zu-hua GAO3,*, Xian-jun QU1,* Synergistic effect of Astragalus flavonoids on breast cancer chemotherapeutic agent 1Department of Pharmacology, School of Basic Medical Sciences, Capital Medical cyclophosphamide based on the regulation of immune function University, Beijing, China; 2Beijing Key Laboratory of Environmental Toxicology, Jing WANG, Xiao LI, Yan-shuang QI, Jia-hui NIE, Xue-mei QIN* Department of Toxicology and Sanitary Chemistry, School of Public Health, Capital Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan Medical University, Beijing, China; 3Department of Pathology, McGill University, 030006, China Montreal, Quebec, Canada *To whom correspondence should be addressed. *To whom correspondence should be addressed. E-mail:
[email protected] E-mail:
[email protected] The present study aimed to observe the synergistic effect of Astragalus flavonoids The resistance mechanisms that limit the efficacy of retinoid therapy in cancer are (TFA) on breast cancer chemotherapeutic agent cyclophosphamide (CTX) and its poorly understood. Sphingosine kinase 2 (SphK2) is a highly conserved enzyme that effect on immunologic function. 4T1 breast cancer bearing mice were established is mainly located in the nucleus and endoplasmic reticulum. Unlike well-studied and then randomly into control group, model group, CTX group (80 mg/kg), sphingosine kinase 1 (SphK1) located in the cytosol, little has yet understood the CTX (80 mg/kg) combined with TFA (6 mg/kg) group and TFA group (6 mg/ functions of SphK2.